# Radiopharmacy and cyclotron networks

Source: https://nuclide.cc/technologies/radiopharmacy-network/  
Nuclide record `radiopharmacy-network` (Technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

The factories and courier routes that make and deliver short-lived radioactive tracers to hospitals within hours.

## Summary

PET tracers (18F, half-life 110 minutes) are produced in regional cyclotron pharmacies and driven or flown to scanners the same day; 68Ga comes from generators or cyclotrons on site; 177Lu and 225Ac therapies are made centrally and shipped globally against decay. Networks: PETNET (Siemens), Cardinal Health, SOFIE, Curium, Jubilant Radiopharma, Isologic/Isorad in Canada, with regional players in Europe and Asia. Capacity and licensing of nuclear pharmacies limits where radioligand therapy can be given.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-09-08
- Tags: supporting
- Principle: Cyclotron proton bombardment or generator elution produces the isotope; automated synthesis modules label the ligand; QC release within an hour; timed logistics deliver a calibrated activity.
- Strengths: Same-day supply of 18F tracers across most high-income regions; Established GMP frameworks
- Limitations: Rural and low-income coverage gaps; Therapy isotope logistics against decay; Single points of failure in reactor supply

## Sources

- 21 CFR Part 212: current good manufacturing practice for PET drugs: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Fluorine-18](https://nuclide.cc/isotopes/f-18/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- technologies: [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://nuclide.cc/technologies/cyclotron-isotope-production/), [DOTA chelation](https://nuclide.cc/technologies/dota-chelation/), [Gamma probes, handheld gamma cameras and dose calibrators](https://nuclide.cc/technologies/gamma-probes-dose-calibrators/), [Medical cyclotrons, hot cells, and synthesis modules](https://nuclide.cc/technologies/medical-cyclotrons-synthesis-modules/), [PET (positron emission tomography)](https://nuclide.cc/technologies/pet/), [PET tracer manufacturing and distribution](https://nuclide.cc/technologies/pet-tracer-manufacturing/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://nuclide.cc/technologies/research-reactor-isotope-production/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://nuclide.cc/technologies/therapy-isotope-supply-chain/)
- companies: [ANSTO (Australian Nuclear Science and Technology Organisation)](https://nuclide.cc/companies/ansto/), [Cardinal Health Nuclear & Precision Health Solutions](https://nuclide.cc/companies/cardinal-health/), [Curium](https://nuclide.cc/companies/curium/), [Eckert & Ziegler](https://nuclide.cc/companies/eckert-ziegler/), [Jubilant Radiopharma](https://nuclide.cc/companies/jubilant-radiopharma/), [PETNET Solutions (Siemens Healthineers)](https://nuclide.cc/companies/petnet-solutions/), [SOFIE Biosciences](https://nuclide.cc/companies/sofie-biosciences/)
- bottlenecks: [Cold chain and time-critical logistics](https://nuclide.cc/bottlenecks/b-cold-chain-logistics/), [Hot lab and shielded treatment room capacity](https://nuclide.cc/bottlenecks/b-hot-lab-capacity/), [Nuclear medicine technologist and physicist workforce](https://nuclide.cc/bottlenecks/b-nuclear-medicine-workforce/), [Radioactive waste handling and disposal regulation](https://nuclide.cc/bottlenecks/b-radioactive-waste-regulation/), [Reimbursement and coding for radiopharmaceuticals](https://nuclide.cc/bottlenecks/b-reimbursement-coding/), [Site readiness and referral pathway delays](https://nuclide.cc/bottlenecks/b-site-readiness-referral/)
- fronts: [Isotope supply](https://nuclide.cc/fronts/f-isotope-supply/)
- ideas: [In-house hospital radiopharmacy compounding to cut dose waste](https://nuclide.cc/ideas/idea-regional-radiopharmacy-network/)
- key papers: [Radiotheranostics: a roadmap for future development](https://nuclide.cc/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/)
- roadmaps: [Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium](https://nuclide.cc/roadmaps/isotope-supply-roadmap/)
- terms: [Radiopharmacy (practice and discipline)](https://nuclide.cc/terms/radiopharmacy-term/)

---
JSON: https://nuclide.cc/api/v1/entities/radiopharmacy-network.json